Skip to content

Study · Observational study · n = 53 · 1991

4 results

Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients.

Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G

Calcified tissue international1 Aug 1991Cited by 75 (Europe PMC)

PMID1913297 (opens in a new tab)DOI10.1007/bf02565124 (opens in a new tab)PepBankPUB-01913297
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In steroid-treated sarcoidosis patients, intramuscular sCT was linked to a very slight vertebral mineral loss versus a large loss without sCT.

    In plain wordsIn steroid-treated sarcoidosis patients, intramuscular sCT was linked to less vertebral mineral loss than no sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseVertebral cancellous mineral content with intramuscular treatment
    Study

    n = 53

    Comparator
    No sCT
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intramuscular · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    We observed a large mineral loss in the third group but a very slight drop of VCMC in the two groups receiving sCT.
    2 context sentences
    Summary · context
    The first group (n = 18) was treated with intramuscular (i.m.) sCT for the 2-year study period; the second (n = 11) with i.m. sCT for the first 4 months and then with sCT nasal spray for 20 months; the third (n = 35) received no sCT.
    Summary · context
    Three groups of patients with sarcoidosis requiring long-term steroid therapy were followed for 2 years with yearly evaluations of vertebral cancellous mineral content (VCMC) by quantitative computed tomography.
  2. 02HumanObservational studyEfficacy outcome

    In steroid-treated sarcoidosis patients, sequential intramuscular and nasal sCT was linked to very slight vertebral mineral loss versus large loss without sCT.

    In plain wordsIn steroid-treated sarcoidosis patients, sequential injected and nasal sCT was linked to less vertebral mineral loss than no sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseVertebral cancellous mineral content with sequential routes
    Study

    n = 46

    Comparator
    No sCT
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · Intramuscular for 4 months, then nasal spray for 20 months · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    We observed a large mineral loss in the third group but a very slight drop of VCMC in the two groups receiving sCT.
    2 context sentences
    Summary · context
    The first group (n = 18) was treated with intramuscular (i.m.) sCT for the 2-year study period; the second (n = 11) with i.m. sCT for the first 4 months and then with sCT nasal spray for 20 months; the third (n = 35) received no sCT.
    Summary · context
    Three groups of patients with sarcoidosis requiring long-term steroid therapy were followed for 2 years with yearly evaluations of vertebral cancellous mineral content (VCMC) by quantitative computed tomography.
  3. 03HumanObservational studySafety outcome

    In steroid-treated sarcoidosis patients, sCT nasal spray was better tolerated than intramuscular injections.

    In plain wordsIn steroid-treated sarcoidosis patients, sCT nasal spray was better tolerated than injections.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedTolerability
    Study

    n: not reported in source

    Comparator
    Intramuscular sCT
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · Nasal spray · 20 months of nasal spray after 4 months of intramuscular treatmentAs given in this study (human).

    Source sentences

    Summary
    SCT nasal spray was better tolerated and as effective as i.m. injections.
    2 context sentences
    Summary · context
    Three groups of patients with sarcoidosis requiring long-term steroid therapy were followed for 2 years with yearly evaluations of vertebral cancellous mineral content (VCMC) by quantitative computed tomography.
    Summary · context
    The first group (n = 18) was treated with intramuscular (i.m.) sCT for the 2-year study period; the second (n = 11) with i.m. sCT for the first 4 months and then with sCT nasal spray for 20 months; the third (n = 35) received no sCT.
  4. 04HumanObservational studyEfficacy outcome

    In steroid-treated sarcoidosis patients, sCT nasal spray was reported as effective as intramuscular injections.

    In plain wordsIn steroid-treated sarcoidosis patients, sCT nasal spray was reported as effective as injections.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedEffectiveness by route
    Study

    n: not reported in source

    Comparator
    Intramuscular sCT
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · Nasal spray · 20 months of nasal spray after 4 months of intramuscular treatmentAs given in this study (human).

    Source sentences

    Summary
    SCT nasal spray was better tolerated and as effective as i.m. injections.
    2 context sentences
    Summary · context
    Three groups of patients with sarcoidosis requiring long-term steroid therapy were followed for 2 years with yearly evaluations of vertebral cancellous mineral content (VCMC) by quantitative computed tomography.
    Summary · context
    The first group (n = 18) was treated with intramuscular (i.m.) sCT for the 2-year study period; the second (n = 11) with i.m. sCT for the first 4 months and then with sCT nasal spray for 20 months; the third (n = 35) received no sCT.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.